Libivirumab: Difference between revisions
No edit summary |
m Protected "Libivirumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
(No difference)
|
Revision as of 20:21, 27 September 2011
WikiDoc Resources for Libivirumab |
Articles |
---|
Most recent articles on Libivirumab Most cited articles on Libivirumab |
Media |
Powerpoint slides on Libivirumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Libivirumab at Clinical Trials.gov Clinical Trials on Libivirumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Libivirumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Libivirumab Discussion groups on Libivirumab Patient Handouts on Libivirumab Directions to Hospitals Treating Libivirumab Risk calculators and risk factors for Libivirumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Libivirumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Libivirumab is a human monoclonal antibody which is used in the treatment of viral infections.